Actualités vTv Therapeutics Inc - VTVT | Actions NASDAQ

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Current Report Filing (8-k)

0001641489 false 0001641489 2023-02-01 2023-02-01 iso4217:USD xbrli:shares...

Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics

HIGH POINT, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage...

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA PR Newswire WESTON, Fla., Jan. 9...

Current Report Filing (8-k)

0001641489 false 0001641489 2023-01-06 2023-01-06 iso4217:USD xbrli:shares...

Current Report Filing (8-k)

0001641489 false 0001641489 2022-12-22 2022-12-22 iso4217:USD xbrli:shares...

Initial Statement of Beneficial Ownership (3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Current Report Filing (8-k)

0001641489 false 0001641489 2022-12-08 2022-12-08 iso4217:USD xbrli:shares...

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer

Steven Tuch, Chief Financial Officer HIGH POINT, N.C., Dec. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics...

vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update

Company on-track to initiate Phase 3 clinical trials of TTP399 in the first quarter of 2023 Industry veteran...

Quarterly Report (10-q)

000164148912-312022Q3false0.500016414892022-01-012022-09-300001641489us-gaap:CommonClassAMember2022-11-10xbrli:s...

Current Report Filing (8-k)

FALSE0001641489NASDAQ00016414892022-11-102022-11-10UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549FORM 8-KCURRENT...

Statement of Ownership (sc 13g)

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Initial Statement of Beneficial Ownership (3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Initial Statement of Beneficial Ownership (3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

vTv Therapeutics Inc (VTVT)

Outils de qualité professionnelle, pour des investisseurs individuels.

VTVT Actualités

Current Report Filing (8-k)

Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA

Current Report Filing (8-k)

Current Report Filing (8-k)

Initial Statement of Beneficial Ownership (3)

Current Report Filing (8-k)

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer

vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update

Quarterly Report (10-q)

Current Report Filing (8-k)

Statement of Ownership (sc 13g)

Statement of Changes in Beneficial Ownership (4)

Initial Statement of Beneficial Ownership (3)

Initial Statement of Beneficial Ownership (3)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

vTv Therapeutics Inc (VTVT) Actualités

vTv Therapeutics Inc (VTVT)

Outils de qualité professionnelle, pour des investisseurs individuels.

VTVT Actualités

Current Report Filing (8-k)

Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA

Current Report Filing (8-k)

Current Report Filing (8-k)

Initial Statement of Beneficial Ownership (3)

Current Report Filing (8-k)

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer

vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update

Quarterly Report (10-q)

Current Report Filing (8-k)

Statement of Ownership (sc 13g)

Statement of Changes in Beneficial Ownership (4)

Initial Statement of Beneficial Ownership (3)

Initial Statement of Beneficial Ownership (3)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités